BIVI - BioVie Seeks $23 Million In Nasdaq IPO

Quick Take

BioVie (OTCQB:BIVI) has filed to raise gross proceeds of $23 million from a U.S. IPO, according to an S-1 registration statement.

The firm is focused on the development of therapies for chronic liver diseases.

BIVI hasn’t entered Phase 1 safety trials yet so is an ultra-early-stage firm. The IPO is likely more appropriate for long-term institutional holders.

I’ll provide a final opinion when we learn further details from management.

Company & Market

Los Angeles, California-based BioVie was founded in 2013 to develop and market new therapies for the treatment of

Read more ...